PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩140 per share · Prices as of the 2026-10-02 close
Built on the steady performance of its placenta-extract injectable Rainek, the company is expanding into botulinum toxin, fillers and skin boosters under a broader medical esthetics strategy.
Annual revenue reached KRW 164.68 billion and operating profit KRW 17.29 billion in 2025, marking four straight years of joint revenue and profit growth with a 10.5% operating margin.
In Q1 2026, operating profit stayed solid at KRW 4.8 billion, yet net profit attributable to owners swung to a KRW 3.0 billion loss before returning to a KRW 4.0 billion profit in Q2.
Rainek maintains its dominant domestic market position, and its high-dose intravenous (IV) formulation met its primary endpoint in a Phase 3 trial.
The company is expanding its esthetics portfolio with the botulinum toxin Inibo (via Inibio), the skin booster Gcelle Ribonne, and fillers, alongside increased new-business investment.
In 2026, GC Biopharma (006280) sold its stake to group holding company GC Holdings (005250), reshaping the affiliate ownership structure within the group.
GC Wellbeing operates a prescription drug business centered on placenta-extract injectables, a clinic-channel health functional food business, and, more recently, a medical esthetics business spanning botulinum toxin, fillers and skin boosters.
Its flagship product, the placenta injectable Rainek, holds roughly 77% share of the domestic placenta injectable market and accounts for a substantial portion of company revenue.
In Korea, Rainek is the only human-placenta hydrolysate product that retained approval after a 2006 regulatory efficacy re-evaluation covering nine competing products, giving it a near-exclusive regulatory position.
Following a 2013 approval by China's State Council to establish the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, Rainek became the first Korean-made placenta injectable to enter an overseas market.
In 2025, GC Wellbeing acquired a controlling 21.35% stake in esthetics company Inibio for roughly KRW 40 billion, gaining the botulinum toxin product Inibo.
Through this subsidiary the company is pursuing an NDA filing and commercialization in China, targeting ANVISA certification and a first shipment in Brazil, and has signed long-term supply agreements covering seven countries.
In 2026 the company launched Gcelle Ribonne, an ECM skin booster based on human acellular dermal matrix (hADM) and the first product under its self-developed Gcelle esthetics brand, while also pursuing entry into the Japanese market.
It has separately secured exclusive domestic development and commercialization rights to a topical fat-dissolving injectable being developed by US-based Radiel Therapeutics, extending its lineup into body-contouring.
On the ownership front, GC Biopharma (006280) sold its 22.1% stake in GC Wellbeing to GC Holdings for roughly KRW 50 billion in cash proceeds during 2026, reshaping the affiliate relationship within the group.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩38.9B | ₩4.2B | 10.8% |
| 2025Q3 | ₩42.3B | ₩5.2B | 12.3% |
| 2025Q4 | ₩48.7B | ₩2.9B | 5.9% |
| 2026Q1 | ₩49.1B | ₩4.8B | 9.8% |
| 2026Q2 | ₩52.1B | ₩4.6B | 8.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩109.7B | ₩8.4B | ₩8B | 7.7% | 8.3% | 56.2% |
| 2023 | ₩120.5B | ₩10.5B | ₩6.7B | 8.7% | 6.7% | 56.0% |
| 2024 | ₩133.8B | ₩13B | ₩7.1B | 9.7% | 6.7% | 53.9% |
| 2025 | ₩164.7B | ₩17.3B | ₩10B | 10.5% | 8.9% | 97.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue rose for four consecutive years, from KRW 109.7 billion in 2022 to KRW 120.5 billion in 2023, KRW 133.8 billion in 2024, and KRW 164.7 billion in 2025.
Operating profit also climbed over the same period from KRW 8.4 billion to KRW 10.5 billion, KRW 13.0 billion and KRW 17.3 billion, lifting the operating margin from 7.7% to 10.5%.
Net profit attributable to owners, however, was less consistent, moving from KRW 8.0 billion in 2022 down to KRW 6.7 billion in 2023 and KRW 7.1 billion in 2024 before recovering to KRW 10.0 billion in 2025.
On a quarterly basis, Q3 2025 posted revenue of KRW 42.3 billion, operating profit of KRW 5.2 billion and net profit of KRW 3.7 billion, while Q4 2025 saw revenue of KRW 48.7 billion, operating profit of KRW 2.9 billion and net profit of only KRW 0.8 billion, reflecting notable swings in operating margin.
Q1 2026 revenue reached KRW 49.1 billion with operating profit of KRW 4.8 billion, a solid operating result that nonetheless coincided with a net loss to owners of KRW 3.0 billion, a divergence between operating performance and bottom-line profit.
Q2 2026 then returned to profitability, with revenue of KRW 52.1 billion, operating profit of KRW 4.6 billion and net profit of KRW 4.0 billion.
According to the company's own disclosure, first-half 2026 consolidated revenue rose 37.4% year over year to KRW 101.2 billion, with operating profit up 2.6% to KRW 9.5 billion.
This growth was driven by Rainek sales of KRW 25.5 billion in the first half alone, combined with an improved cost ratio as the Eumseong innovation plant's utilization rate rose alongside higher production volumes.
Separately, the debt ratio jumped to 97.2% in 2025 from 53.9% in 2024, while operating cash flow fell from KRW 13.7 billion in 2024 to KRW 5.7 billion in 2025, indicating a heavier financial burden from expanded new-business investment.
In the domestic placenta injectable market, Rainek is the only product that survived a regulatory efficacy re-evaluation, giving the segment high barriers to new entry.
By contrast, the esthetics market for fillers, toxins and skin boosters is a competitive growth segment with multiple domestic players; Hans Biomed, for instance, is seen as having gained a stronger foothold in the domestic market by securing a large esthetics distribution network.
ECM-based skin boosters in particular are differentiating themselves from earlier collagen-inducing products by injecting human-derived acellular dermal matrix (hADM) components in micro-particle form to reconstruct and regenerate damaged skin tissue matrix.
The botulinum toxin market is characterized by intense competition among domestic makers seeking overseas approvals for export growth, and GC Wellbeing, through Inibio, is pursuing emerging-market approvals including an NDA filing in China and ANVISA certification in Brazil.
China's Hainan international medical tourism pilot zone offers an expedited approval pathway that Korean pharmaceutical and esthetics companies have used for pilot market entry, and the company has built up its China track record for Rainek through this channel.
Relative to peers, the company's differentiator is its near-exclusive cash-generating Rainek franchise, though in the newer esthetics business it remains a later entrant competing against already-established players.
Rainek's high-dose intravenous drip formulation reported topline Phase 3 results meeting its primary endpoint, and the company plans to file for Ministry of Food and Drug Safety approval within the year.
Industry observers note that if the IV formulation is approved, it could expand the pool of treated patients through supply to tertiary general hospitals.
Samsung Securities noted in a May 2025 report that the company plans to switch Rainek's container format from ampoules to vials in 2027, alongside an expected price increase of around 30%.
On the esthetics side, Inibio's botulinum toxin Inibo is pursuing commercialization in emerging markets through an NDA review in China and certification in Brazil, having already signed long-term supply agreements covering seven countries.
The skin booster Gcelle Ribonne, following its domestic launch, is also being positioned for entry into the Japanese market, while the company is pursuing domestic development and approval of a fat-dissolving injectable licensed from US-based Radiel Therapeutics, extending its product range into body-contouring.
The company itself has projected that esthetics revenue contribution will rise and accelerate growth further into the second half. It had previously stated a target of bringing Rainek into mainland China by 2026, making progress on this goal worth confirming before year-end.
Revenue and operating profit have grown steadily in recent years, and net profit also showed a recovery in 2025, though quarterly volatility remains, as seen in the temporary swing to a net loss attributable to owners in Q1 2026.
The market's assessment of this earnings stability appears to be partly reflected in the current level at which the stock trades relative to net asset value.
The company has maintained a policy of annual cash dividends, but with the financial burden from expanded esthetics investment increasing, the future direction of dividend policy is a point worth watching.
The stock's valuation appears to reflect both Rainek's stable cash generation and the growth potential of the esthetics business simultaneously, and how quickly new-business revenue contribution becomes visible could shift market assessment going forward.
The sharp rise in the debt ratio is a variable that should be weighed alongside the stock's valuation relative to net asset value.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Rainek holds around 77% share of the domestic placenta injectable market as the only product to survive a regulatory efficacy re-evaluation, giving it a high regulatory barrier to entry.
This is complemented by the potential for expanded prescriptions following the successful Phase 3 result for its high-dose IV formulation, diversifying growth drivers. This stable cash generation underpins investment in new business lines.
Through the Inibio acquisition the company secured botulinum toxin, through Gcelle Ribonne an ECM skin booster, and through the Radiel Therapeutics license a fat-dissolving injectable, building a lineup spanning fillers, toxin, skin boosters and body-contouring. Cross-selling potential with its existing distribution network could accelerate new-product adoption.
Operating margin improved steadily from 7.7% in 2022 to 10.5% in 2025, and the trend of cost-ratio improvement from higher plant utilization continued into the first half of 2026. If profitability improvement continues, it could build capacity to offset the burden of new-business investment.
In Q1 2026, despite solid operating profit of KRW 4.8 billion, net profit attributable to owners swung to a KRW 3.0 billion loss, creating a divergence between operating results and the bottom line. This kind of volatility, driven by non-operating factors, raises uncertainty in forecasting quarterly results.
The debt ratio jumped to 97.2% in 2025 from 53.9% in 2024, while operating cash flow fell from KRW 13.7 billion in 2024 to KRW 5.7 billion in 2025. This suggests that funding needs for esthetics investment and acquisitions are weighing on the balance sheet.
The filler, toxin and skin booster market already features established competitors with built-out distribution and brands, and GC Wellbeing, as a relative late entrant, may need to keep spending on marketing. There is also a risk that revenue contribution could lag behind investment until new products gain traction.
With the debt ratio up roughly 44 percentage points in a single year and operating cash flow declining, further acquisitions or investments could increase the need for external financing.
Convertible bonds were previously issued to fund the Inibio stake purchase, so potential share dilution from similar future financing methods is worth monitoring.
Multiple domestic and overseas approval processes are underway simultaneously, including China's NDA review, Brazil's ANVISA certification, and MFDS approval for Rainek's IV formulation. A delay in any one of these could push back the associated revenue contribution timeline.
In 2026, GC Biopharma (006280) sold its stake to group holding company GC Holdings, reshaping affiliate governance within the group. The impact of this ownership shift on future group strategy or inter-affiliate cooperation warrants ongoing monitoring.
The Q3 preliminary earnings release will show the revenue contribution and margin trend from new esthetics products.
Progress on the MFDS approval filing for Rainek's high-dose IV formulation should be checked.
Watch for the outcome of Inibio's botulinum toxin NDA review in China and whether Brazilian shipments begin following ANVISA certification.
It is worth confirming whether the company's stated goal of bringing Rainek into mainland China materializes within the year.
Check whether Rainek's planned switch from ampoules to vials and the associated price increase are implemented, and how this affects revenue and margins.
GC Wellbeing is in a phase of expanding beyond its near-exclusive placenta injectable cash cow, Rainek, into botulinum toxin, fillers, skin boosters and fat-dissolving injectables.
Revenue and operating profit grew steadily from 2022 through 2025 with improving operating margins, but quarterly volatility, such as the temporary net loss in Q1 2026, is a factor that warrants continued observation.
The sharp rise in the debt ratio and decline in operating cash flow reflect expanded esthetics investment and should be watched alongside the balance sheet changes.
Multiple variables are progressing in parallel, including overseas approvals in China and Brazil, MFDS approval for Rainek's IV formulation, and the reshaping of group governance, meaning the future direction of results could depend on how quickly these events unfold.
This report does not provide an investment opinion or target price, and any buy or sell decision remains the reader's own responsibility.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.